| To: canbballtrader who wrote (42) | 8/2/2005 2:44:30 PM | | From: jmhollen | | | | Subject 55842
mafia.ocm = pinksheets.com. Less keystrokes, and it makes fun of the 'Streeter Stock' Snobs around here.....
NNVC is in the middle of their go-to-OTCBB audit, and blew off updating Pinksheets, so Pinksheets retaliated (..bunch of azzholes..) by stopping their quotes with no warning.
Free RealTime.com will give you Time & Sales on NNVC (..paying for FRT Express is recommended..), and you can interpolate from that. I just bought 30K at 0.018.
John :-)
. |
| | NNVC - NanoViricides, Inc. | Stock Discussion ForumsShare | RecommendKeepReplyMark as Last ReadRead Replies (1) |
|
| To: rrufff who wrote (44) | 8/2/2005 5:24:53 PM | | From: jmhollen | | | | They're flying under the radar, doing the audit, and getting new products ready for launch.... ..Sounds like we'll get hit with a barrage next month....
Buy while the mafia.com quotes are hosed, when they're back (..with RTQs and L-II, I hope..) it should rebound quickly...
John :-)
. |
| | NNVC - NanoViricides, Inc. | Stock Discussion ForumsShare | RecommendKeepReplyMark as Last Read |
|
| From: jmhollen | 8/3/2005 12:48:43 PM | | | | | | "..Wheeeeeeeeeeeeeeeeeeeeeeeeee.......... ..I snagged another 10K for $0.175 during the noon sale...........
This is going to be fun when they get the mafia.com quotes fixed....
John :-)
. |
| | NNVC - NanoViricides, Inc. | Stock Discussion ForumsShare | RecommendKeepReplyMark as Last Read |
|
| From: donpat | 8/4/2005 11:27:34 AM | | | | | | NanoViricides Retains Auditor in Preparation of Filing Form 10-SB
Thursday August 4, 11:14 am ET
NEW YORK--(BUSINESS WIRE)--Aug. 4, 2005--NanoViricides, Inc. (Pink Sheets:NNVC - News; the "Company"), announced today that it had retained Bloom & Co., LLP of Hempstead, New York as its independent auditors, in anticipation of filing Form 10-SB and being quoted on the OTC bulletin board quotation system.
Commenting upon the retention, Leo Ehrlich, NanoViricides' Chief Financial Officer stated, "this is a very exciting time for NanoViricides. Retaining PCAOB registered auditors such as Bloom & Company will enable the Company to complete its first ever audit, an important step in our goal of becoming a reporting company. Upon completion of the Company's audited financial statements, we anticipate immediately filing a Form 10-SB to commence reporting obligations with the Securities and Exchange Commission. Becoming a reporting company with the objective of having our stock quoted on the OTC Bulletin Board is a positive step for the company and for our shareholders."
About NanoViricides - nanoviricides.com
NanoViricides, Inc. is a development stage company that is creating special purpose nanomaterials for viral therapy. NanoViricides, Inc. has exclusive license in perpetuity for technologies developed by Theracour Pharma for the five virus types HIV, HCV, Herpes, Asian (bird) flu and Influenza. A NanoViricide(TM) is a nanoparticle that contains an encapsulated active pharmaceutical ingredient and targets it to a specific type of virus. When a NanoViricide(TM) drug particle enters the patient's blood stream, it attacks and immobilizes circulating virus particles. Once this is done, the active pharmaceutical ingredient is injected into the virus by the NanoViricide(TM) particle, destroying it. The company plans to develop novel NanoViricide(TM) drugs first against HIV, and market its products to major pharmaceutical companies.
Contact:
NanoViricides, Inc., New York
Leo Ehrlich, 917-853-6440
leo@nanoviricides.com
or
Anil R. Diwan, Ph.D.
adiwan@snet.net
Source: NanoViricides, Inc.
biz.yahoo.com |
| | NNVC - NanoViricides, Inc. | Stock Discussion ForumsShare | RecommendKeepReplyMark as Last Read |
|
| From: jmhollen | 8/4/2005 7:40:01 PM | | | | | | I found this a rather interesting read: nanoviricides.com
One of our crew who is a Doctor currently in surgical practice is going to do a little mining from his end. So, we'll see what his opinions about the potential therapies are shortly.
John :-)
. |
| | NNVC - NanoViricides, Inc. | Stock Discussion ForumsShare | RecommendKeepReplyMark as Last Read |
|
| From: donpat | 8/5/2005 3:38:52 PM | | | | | | Missed opportunities in nano
August 05, 2005
Nanotechnology companies are missing opportunities to help corporate buyers integrate nanoscale components into advanced products, experts told UPI's Nano World.
[Snip]
Lux Research sees nanotech services emerging in healthcare and life sciences, particularly in making existing blockbuster drugs more effective. For instance, Abraxane is made of nanoparticles containing the tumor-fighting drug paclitaxel bound to albumin protein. Abraxane can be taken without the toxic solvents normally used with paclitaxel, which means more of the drug can be taken with fewer side effects.
Lackner noted that Debiopharm in Lausanne, Switzerland, has partnered with NanoCarrier in Tokyo to reformulate their cancer treatment Eloxatin. NanoCarrier's micellar nanoparticles could "allow Debiopharm to extend the lifetime of its cash cow, which generated $1.5 billion in revenue in 2004," he said.
"More pharma giants will seek such capabilities as the impact of initial successes like American Pharmaceutical Partners' Abraxane kicks in and as reformulators like Elan deliver more winning products," Lackner added. "Companies that enter this underserved field with low-cost deals to prove their worth will transform themselves into long-term partners deserving premium prices."
physorg.com |
| | NNVC - NanoViricides, Inc. | Stock Discussion ForumsShare | RecommendKeepReplyMark as Last Read |
|
| From: donpat | 8/6/2005 8:17:56 AM | | | | | | HIV 'could destroy cancer cells'
US scientists hope to be able to use a harmless form of the Aids virus to seek and destroy cancer cells.
A University of California team found an "impotent" version of HIV, with the disease-causing parts of it removed, tracked down cancer cells in mice.
The next step would be to insert a gene into the virus that would kill the cancer upon contact.
The team told Nature Medicine more safety studies were needed before such a method could be tested in humans.
Gene therapy
The mice they studied had a form of skin cancer, called melanoma, that had spread to the lungs.
In the laboratory, the scientists took HIV and removed the parts of the virus that causes disease.
They then stripped off the virus' outer coat and redressed it with the outer suit of another virus.
By doing this, the researchers had changed the target of the virus.
HIV normally infects immune cells called T cells. The new outer coat instead directed HIV to hunt down molecules present on cancer cells, called P-glycoproteins.
The scientists also added a substance to the virus that would make it visibly glow when looked at with a special camera so they could track where it travelled once injected into the mice.
Researcher Dr Irvin Chen, from UCLA's Aids Institute, said: "The virus travelled through the bloodstream and homed straight to the cancer cells in the lungs, where the melanoma had migrated.
"Gene therapy has been hampered by the lack of a good carrier.
"Our approach proves that it is possible to develop an effective carrier and reprogram it to target specific cells in the body."
Beating cancer's spread
His team is planning to see whether the virus could carry a therapeutic gene to the precise location of the cancer.
As well as controlling cancer, they hope this technique might be useful for treating genetic diseases.
Dr Georges Vassaux, from Cancer Research UK's clinical centre at Barts and The London, said: "This is the first time that a vector - or delivery system - for gene therapy has targeted a tumour in such a specific manner.
"This means the technique could be used to use gene therapy in cases where cancer has spread around the body.
"So far gene therapy has been successfully used only on tumours that are confined to their original location."
He said there had been concerns that such methods might cause leukaemia in normal cells.
"As the team has managed to target the therapy to cancer cells, it looks as though a hazard associated with the use of integrative viruses may have been overcome," he said.
news.bbc.co.uk
newsroom.ucla.edu
|
| | NNVC - NanoViricides, Inc. | Stock Discussion ForumsShare | RecommendKeepReplyMark as Last Read |
|
| From: donpat | 8/10/2005 2:44:53 PM | | | | | | A 'Smart' Bio-Nanotube
Santa Barbara CA (SPX) Aug 10, 2005
By combining one natural component of a cell with the synthetic analog of another component, researchers at the University of California, Santa Barbara, have created a nanoscale hybrid they call the "smart bio-nanotube": a novel structure that could one day become a vehicle for ultra-precise drug or therapeutic gene delivery.
The nanotubes are "smart" because they can open or close at the ends, depending on how the researchers manipulate the electric charge on the two components. So in principle, a nanotube could encapsulate a drug or a gene, and then open on command to deliver the cargo where it would have the best effect.
The tube's components play roles similar to skin and bone. The "skin" is a soap-bubble-like arrangement of molecules known as a lipid bilayer, akin to the bilayer that forms the cell's protective outer membrane.
The "bone" is a hollow, cylindrical structure known as a microtubule, which is ubiquitous in the cell's internal cytoskeleton, the system of nanoscale struts and girders it uses for internal transport, structural stability and many other purposes.
The researchers have found that when they combine the two components and control the conditions properly, open or closed bio-nanotubes will assemble themselves spontaneously.
The discovery resulted from a collaboration between the laboratories of UCSB materials scientist Cyrus R. Safinya, and UCSB biochemist Leslie Wilson. Their work was funded by the National Science Foundation's biomaterials program and is reported in the Aug. 9 issue of The Proceedings of the National Academy of Sciences. The report also appeared on-line in the PNAS Early Edition.
Image:
nsf.gov
Image caption:
"Smart" bionanotubes. Lipid protein nanotubes made of microtuble protein (made of tubulin protein subunits shown as red-blue-yellow-green objects) that is coated by a lipid bilayer (drawn with yellow tails and green and white spherical heads) which in turn is coated by tubulin protein rings or spirals. By controlling the relative amount of lipid and protein it is possible to switch between two states of nanotubes with either open ends (shown in the center) or closed ends with lipid caps (shown on the left), a process which forms the basis for controlled chemical and drug encapsulation and release. A top view of the nanotubes and a magnified region is shown on the right. The image was created by Peter Allen. See larger image.
terradaily.com
***************************
This nano-bio stuff with cancer curing/drug delivering functions is coming fast and furious, these days, with carbon nanotubes figuring prominently therein.
***************************
The PNAS material
Published online before print July 29, 2005, 10.1073/pnas.0502183102
PNAS | August 9, 2005 | vol. 102 | no. 32 | 11167-11172
APPLIED PHYSICAL SCIENCES
Cationic liposome–microtubule complexes: Pathways to the formation of two-state lipid–protein nanotubes with open or closed ends
Uri Raviv *, , , , ¶, Daniel J. Needleman *, , , , Youli Li *, , , , Herbert P. Miller , , Leslie Wilson , and Cyrus R. Safinya *, , , , ¶
Departments of *Materials, Physics, and Molecular, Cellular, and Developmental Biology, Biomolecular Science and Engineering Program, University of California, Santa Barbara, CA 93106
Edited by Michael E. Fisher, University of Maryland, College Park, MD, and approved June 14, 2005 (received for review March 17, 2005)
Intermolecular interactions between charged membranes and biological polyelectrolytes, tuned by physical parameters, which include the membrane charge density and bending rigidity, the membrane spontaneous curvature, the biopolymer curvature, and the overall charge of the complex, lead to distinct structures and morphologies. The self-assembly of cationic liposome–microtubule (MT) complexes was studied, using synchrotron x-ray scattering and electron microscopy. Vesicles were found to either adsorb onto MTs, forming a "beads on a rod" structure, or undergo a wetting transition and coating the MT. Tubulin oligomers then coat the external lipid layer, forming a tunable lipid–protein nanotube. The beads on a rod structure is a kinetically trapped state. The energy barrier between the states depends on the membrane bending rigidity and charge density. By controlling the cationic lipid/tubulin stoichiometry it is possible to switch between two states of nanotubes with either open ends or closed ends with lipid caps, a process that forms the basis for controlled chemical and drug encapsulation and release.
polyelectrolyte lipid complexes | small angle x-ray scattering | nanotube-based drug delivery | membrane | tubulin
Author contributions: U.R. and C.R.S. designed research; U.R. and D.J.N. performed research; U.R., Y.L., H.P.M., and L.W. contributed new reagents/analytic tools; U.R. and C.R.S. analyzed data; and U.R. and C.R.S. wrote the paper.
This paper was submitted directly (Track II) to the PNAS office.
Abbreviations: PLC, polyelectrolyte–lipid complex; MT, microtubule; SAXRD, small angle x-ray diffraction; TEM, transmission electron microscopy; LPN, lipid–protein nanotube; BOR, beads on a rod; DLTAP, dilauryl(C12:0)-trimethyl ammonium propane; DOTAP, dioleoyl(C18:1)-trimethyl ammonium propane; DPTAP, dipalmitoyl(C16:0)-trimethyl ammonium propane; PC, phosphatidylcholine; DLPC, dilauryl(C12:0)-PC; DOPC, dioleoyl(C18:1)-PC; DPPC, dipalmitoyl(C16:0)-PC.
|| The mean electron density of tubulin is obtained from the partial specific volume of tubulin (0.725 ml/g) (35), the ratio between the electron and mass densities (0.5445 e/g, calculated based on the primary tubulin structure) and the mean volume of the tubulin unit cell within the MT wall (5 x 5 x 8 nm3) (34). Assuming the rest of the tubulin unit cell volume is occupied by water molecules (of density 333 e/nm3) we find that the mean electron density of the MT wall is 411 e/nm3.
** Fluctuations are effectively included by allowing the lipid tail length and inner MT radius (8.1 nm) to change within physically reasonable limits. The third tubulin layer is assumed to have the mirror image of the inner MT wall electron density profile (taken from the MT fitted model), to reflect what we believe is the correct orientation of the tubulin dimers in the outer layer. It is perpendicular to the internal MT protofilament direction and the side of the dimer facing the MT lumen is flipped inside out (Fig. 1 D and E). Using three different lipid solutions with different tail lengths, we obtained the expected shifts in the form factor, indicating that we identify correctly the location of the lipid bilayer.
¶ To whom correspondence may be addressed. E-mail: raviv@mrl.ucsb.edu or safinya@mrl.ucsb.edu.
© 2005 by The National Academy of Sciences of the USA
pnas.org |
| | NNVC - NanoViricides, Inc. | Stock Discussion ForumsShare | RecommendKeepReplyMark as Last ReadRead Replies (1) |
|
| |
